
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
Arcturus Therapeutics (ARCT) Analyst Ratings
Bulls say
Arcturus Therapeutics Holdings Inc. is positioned favorably within the RNA medicines sector, with promising advancements in its pipeline targeting liver and respiratory diseases. Recent preliminary data indicates a noteworthy improvement in forced expiratory volume (FEV1) among treated patients, with a reported average absolute increase of 3.8% and a relative increase of 5.1% from baseline to Day 42, despite acknowledging the need for cautious interpretation of these exploratory results. Additionally, the company's innovative approach, including the newly developed assay for measuring urea cycle function, along with its ongoing efforts in intellectual property defense, underscore the potential for enhanced commercial viability and value creation in the future.
Bears say
Arcturus Therapeutics Holdings Inc. faces a negative outlook primarily due to disappointing interim data from its ARCT-032 Phase 2 trial, which failed to demonstrate a meaningful improvement in FEV1, leading to the removal of this asset from the company's valuation model. Additionally, the potential for delays in clinical trials or unexpected safety and efficacy issues for several key pipeline products increases downside risk and contributes to a lower market confidence in the company's future prospects. Furthermore, Arcturus's inability to defend its patents raises the threat of increased competition from generic alternatives, further complicating its position in the market.
This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares